CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Fragmentation of Diagnostic Imaging Leading to a Management Error in a Patient With Small-Cell Lung Cancer Fig 2. Summary of guideline recommendations. AEs, adverse ...
1don MSN
Overlooked hormone may be deadly driver of postmenopausal breast cancer in women with obesity
A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be ...
Emerging evidence suggests there may be a critical window for estrogen therapy to protect against cognitive decline later in ...
The drug dexamethasone supplements cancer treatments to alleviate side effects of chemotherapy such as nausea or inflammation ...
Triple-negative breast cancer (TNBC) is notoriously difficult to treat because it is quite aggressive and the tumors do not express the three major surface hormone receptors that can be targeted with ...
The MHRA has approved inavolisib for adults with PIK3CA-mutated HR+/HER2– breast cancer, offering a new targeted first-line ...
Researchers from the University of Leipzig and Shandong University have recognized GPR133, a receptor in bone-forming cells, ...
News-Medical.Net on MSN
Dexamethasone shows potential to fight therapy-resistant breast cancer metastases
The drug dexamethasone supplements cancer treatments to alleviate side effects of chemotherapy such as nausea or inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback